Benefits
Acute diarrhea — supports faster recovery in children
B. clausii reduces duration and severity of acute diarrhea in children and adults across multiple randomized trials. Effect sizes are moderate; benefits seen within days of starting supplementation. One of the better-evidenced uses for this strain.
Antibiotic-associated diarrhea prevention
Taken alongside antibiotic therapy, B. clausii may help reduce diarrhea during antibiotic courses (best shown during H. pylori eradication). Heat-stable spore form means it survives stomach acid intact and isn't killed by concurrent antibiotic doses — unlike lactic acid bacteria probiotics.
H. pylori therapy — digestive comfort/tolerability support
Used alongside standard triple therapy for H. pylori infection, B. clausii reduces side effects of antibiotic therapy and may improve patient compliance. Adjunct support; not standalone treatment.
Spore-form survival advantage
The spore form is heat-stable and acid-resistant, surviving stomach acid intact to germinate in the small intestine. Distinguishing mechanism — most probiotic forms require refrigeration and significant doses to compensate for stomach acid loss.
Antimicrobial peptide production
In laboratory studies, B. clausii can produce antimicrobial peptides (bacteriocins) that inhibit some bacteria — a proposed mechanism (not a demonstrated clinical anti-infective effect) that offers a plausible rationale for its gut-support use.
Decades-long safety record
Marketed in Europe and emerging markets since the 1950s with extensive real-world safety data across millions of users. Generally well-tolerated, including in young children; avoid in immunocompromised individuals due to a rare risk of bacteremia (see side effects).
Mechanism of action
Intrinsic polyantibiotic resistance (uniquely positioned)
Natural genetic resistance to multiple antibiotic classes — distinct from acquired resistance via plasmid transfer. Allows the probiotic to survive and exert effects during concurrent antibiotic therapy, the central practical advantage for AAD prevention.
Spore-forming durability
Bacterial endospores are dormant, resistant structures surviving heat, acid, bile, and processing. Spores germinate to active vegetative cells in the small intestine where they exert effects.
Antimicrobial peptide production
B. clausii can produce antimicrobial peptides (bacteriocins) shown in laboratory studies to inhibit some opportunistic bacteria. This is a proposed mechanism rather than a demonstrated clinical anti-infective effect in humans.
Microbiota restoration during dysbiosis
During antibiotic-induced dysbiosis, B. clausii occupies niche space and supports recovery of native commensals. Mechanism for reduced AAD development.
Anti-inflammatory effects
Reduces pro-inflammatory cytokine production in the gut mucosa — supporting recovery from inflammatory diarrhea episodes.
Clinical trials
Systematic review and meta-analysis of randomized controlled trials of B. clausii for acute diarrhea in children. (Ianiro et al. 2018, Nutrients; PMID 30103531). Note: several included trials are small and industry (Sanofi)-linked.
Children with acute diarrhea across pooled randomized controlled trials.
Meta-analysis indicated B. clausii shortened the duration of acute diarrhea in children versus control. Effect is meaningful but modest, and several pooled trials were small and Sanofi-linked, so the evidence is best described as moderate rather than definitive.
Randomized, double-blind, placebo-controlled trial of B. clausii during H. pylori eradication therapy. (Nista et al. 2004, Aliment Pharmacol Ther; PMID 15569121).
Adults undergoing standard H. pylori eradication (antibiotic) therapy.
B. clausii reduced antibiotic-associated side effects (diarrhea, nausea) during H. pylori eradication therapy versus placebo, supporting its adjunct use for treatment tolerability. Symptom-level benefit.
Double-blind, placebo-controlled RCT of B. clausii in children under 5 with diarrhea. Uses commercial strain UBBC-07, which differs from the Enterogermina O/C, N/R, SIN, T strains, so relevance to this product is indirect. (Sudha et al. 2019, Benef Microbes; PMID 30638396).
Children under 5 years of age with acute diarrhea.
B. clausii (strain UBBC-07) reduced diarrhea severity/duration versus placebo. Benefit was modest, and because this is a different commercial strain than Enterogermina’s, applicability to this specific product is indirect.